Genetic Polymorphism of MDM2 SNP309 in Patients with Helicobacter Pylori-Associated Gastritis

  • Tongtawee, Taweesak (Department of Surgery, Suranaree University of Technology) ;
  • Dechsukhum, Chavaboon (Pathological Unit, Institute of Medicine, Suranaree University of Technology) ;
  • Leeanansaksiri, Wilairat (Parasite Research Unit and Institute of Science, Suranaree University of Technology) ;
  • Kaewpitoon, Soraya (Family Medicine and Community Medicine, Suranaree University of Technology) ;
  • Kaewpitoon, Natthawut (Parasite Research Unit and Institute of Science, Suranaree University of Technology) ;
  • Loyd, Ryan A (Family Medicine and Community Medicine, Suranaree University of Technology) ;
  • Matrakool, Likit (Department of Surgery, Suranaree University of Technology) ;
  • Panpimanmas, Sukij (Department of Surgery, Suranaree University of Technology)
  • Published : 2015.11.04


Background: Helicobacter pylori plays an important role in gastric cancer, which has a relatively low inciduence in Thailand. MDM2 is a major negative regulator of p53, the key tumor suppressor involved in tumorigenesis of the majority of human cancers. Whether its expression might explain the relative lack of gastric cancer in Thailand was assessed here. Materials and Methods: This single-center study was conducted in the northeast region of Thailand. Gastric mucosa from 100 patients with Helicobacter pylori associated gastritis was analyzed for MDM2 SNP309 using real-time PCR hybridization (light-cycler) probes. Results: In the total 100 Helicobacter pylori associated gastritis cases the incidence of SNP 309 T/T homozygous was 78 % with SNP309 G/T heterozygous found in 19% and SNP309 G/G homozygous in 3%. The result show SNP 309 T/T and SNP 309 G/T to be rather common in the Thai population. Conclusions: Our study indicates that the MDM2 SNP309 G/G homozygous genotype might be a risk factor for gastric cancer in Thailand and the fact that it is infrequent could explain to some extent the low incidence of gastric cancer in the Thai population.


  1. Bond GL, Menin C, Bertorelle R, et al (2006). MDM2 SNP309 Accelerates colorectal tumour formation in women. J Med Genet, 43, 950-2.
  2. Bond GL, Hu W, Bond EE, et al (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.
  3. Bond GL, Hirshfield KM, Kirchhoff T, et al (2006). MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res, 66, 5104-10.
  4. Economopoulos KP, Sergentanis TN (2010). Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat, 120, 211-6.
  5. Haupt Y, Maya R, Kazaz A, Oren M (1997). Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-9.
  6. Honda R, Tanaka H, Yasuda H (1997). Oncoprotein MDM2 is ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett, 420, 25-7.
  7. Hu Z, Jin G, Wang L, et al (2007). MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev, 16, 2717-23.
  8. Inuzuka H, Tseng A, Gao D, et al (2010). Phosphorylation by casein kinase I promote the turnover of the Mdm2 oncoprotein via the SCF (beta-TRCP) ubiquitin ligase. Cancer Cell, 18, 147-59.
  9. Inuzuka H, Fukushima H, Shaik S, et al (2010). Novel insights into the molecular mechanisms governing mdm2 ubiquitination and destruction. Oncotarget, 1, 685-90.
  10. Kubbutat MH, Jones SN, Vousden KH (1997). Regulation of p53 stability by Mdm2. Nature, 387, 299-303.
  11. Knappskog S, Bjornslett M, Myklebust LM, et al (2011). The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell, 19, 273-82.
  12. Knappskog S, Trovik J, Marcickiewicz J, et al (2011). Impact of the MDM2 promoter polymorphsims SNP285 and SNP309 on endometrial cancer risk among Caucasians. ASCO, 5092.
  13. Landers JE, Cassel SL, George DL (1997). Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res, 57, 3562-8.
  14. Martin K, Trouche D, Hagemeier C, et al (1995). Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature, 375, 691-4.
  15. Momand J, Jung D, Wilczynski S, Niland J (1998). The MDM2 gene amplification database. Nucleic Acids Res, 26, 3453-9.
  16. Momand J, Wu HH, Dasgupta G (2000). MDM2-master regulator of the p53 tumor suppressor protein. Gene, 242, 15-29.
  17. Moradi MT, Salehi Z, Aminian K, et al (2014). Effects of p53 codon 72 and MDM2 SNP309 polymorphisms on gastric cancer risk among the Iranian population. Asian Pac J Cancer Prev, 15, 7413-7.
  18. Oliner JD, Kinzler KW, Meltzer PS, et al (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80-83.
  19. Post SM, Quintas-Cardama A, Pant V, et al (2010). A high-frequency regulatory polymorphism in the p53 pathwayaccelerates tumor development. Cancer Cell, 18, 220-30.
  20. Rayburn E, Zhang R, He J, et al (2005). MDM2 and human malignancies: expression, clinical pathology, prognostic markers and implications for chemotherapy. Curr Cancer Drug Targets, 5, 27-41.
  21. Sheikh MS, Shao ZM, Hussain A, et al (1993). The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res, 53, 3226-8.
  22. Trotta R, Vignudelli T, Candini O, et al (2003). BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell, 3, 145-60.
  23. Xiao ZX, Chen J, Levine AJ, et al (1995). Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature, 375, 694-8.
  24. Wang X, Yang J, Ho B, et al (2009). Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter is associated with gastric cancer susceptibility in Chinese patients. Helicobacter, 14, 114-9.

Cited by

  1. Toll-Like Receptors are Associated with Helicobacter pylori Infection and Gastric Mucosa Pathology vol.In Press, pp.In Press, 2017,
  2. Genetic polymorphisms in TLR1, TLR2, TLR4, and TLR10 of Helicobacter pylori-associated gastritis vol.27, pp.2, 2018,